Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06626737
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-02
Brief Title:
Dapagliflozin in Allo-HCT for AGVHD
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Dapagliflozin for Preventing Acute Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation a Prospective Single-Arm Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DAPALAG-01
Brief Summary:
The goal of this clinical trial is to learn if Dapagliflozin could prevent acute graft-versus-host disease aGVHD in patients undergoing allogeneic hematopoietic cell transplantation allo-HCT and to assess its safety The main questions it aims to answer are Dose Dapagliflozin lower the cumulative incidence of aGVHD What medical problems do participants undergoing allo-HCT have when taking Dapagliflozin Researchers will document the occurrence of graft-versus-host disease hematopoietic reconstitution survival rates and adverse effects Participants will take Dapagliflozin every day in -1 to 14 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None